VAL401 results accepted for journal publication, says ValiRx

Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.

The AIM-traded firm said the peer-reviewed article will appear in the journal early in 2019.

It explained that the article would detail and analyse the pharmacokinetic data acquired during the VAL401 Phase II clinical trial, which was concluded in Tbilisi, Georgia in 2017.

VAL401 was described by the board as a new formulation of the antipsychotic drug ‘risperidone’, enabling the company’s oncology treatment.

The analysis reportedly considered the clinical significance of the VAL401 results in comparison to previously-reported data for conventional risperidone, providing a theoretical insight into the altered activity of the therapeutic.

“I'm delighted to be able to announce acceptance for publication of this article, which is intended to be the first in a series of results-based publications on VAL401,” said ValiRx chief executive officer Dr Suzy Dilly.

“Peer-reviewed publications are always interesting to complete, as the article is very much shaped and expanded by the anonymous expert reviewers, providing a respected validation of the data.”